Sign in to continue:

Saturday, March 7th, 2026

Wise Ally International Issues Profit Warning: Expects HK$33 Million Net Loss for 2025 Amid US Tariffs and Trade Tensions 1





Wise Ally International Issues Profit Warning for FY2025

Wise Ally International Issues Significant Profit Warning for FY2025

Wise Ally International Holdings Limited (Stock Code: 9918) has issued a formal profit warning, alerting shareholders and potential investors to a dramatic downturn in its financial performance for the year ended 31 December 2025.

Key Highlights of the Announcement

  • Expected Net Loss: The Group anticipates a net loss attributable to equity holders of approximately HK\$33.0 million for FY2025. This marks a sharp reversal from the previous year, during which the Group posted a net profit of approximately HK\$72.2 million for FY2024.
  • Revenue Decline: The loss is primarily attributed to a significant decline in revenue. This downturn is a direct result of external macroeconomic and geopolitical factors.
  • Impact of U.S. Tariffs and Trade Tensions: The company specifically cites the imposition of additional U.S. tariffs on its export product category, as well as ongoing international trade tensions, as key contributors to the adverse performance. These factors have led major customers to adopt a much more cautious stance, resulting in the deferral or reduction of purchase orders.

Detailed Financial Assessment

The Board emphasizes that the figures disclosed are based on the preliminary review of unaudited consolidated management accounts for the year ended 31 December 2025. The results have not yet been audited or reviewed by the company’s auditors. Therefore, the final audited numbers—expected to be published by the end of March 2026—may differ from the figures outlined in this announcement.

Implications for Shareholders and Investors

  • Price Sensitive Information: The switch from a substantial profit in 2024 to a significant loss in 2025 is a major financial event and likely to have a material impact on the company’s share price.
  • External Risks: The reliance on export markets and exposure to international trade dynamics, including tariff regimes and geopolitical uncertainty, introduces ongoing risks to Wise Ally’s revenue streams.
  • Guidance for Investors: The Board specifically advises shareholders and potential investors to exercise caution when dealing in the shares of the Company. Investors are further urged to await the official annual results announcement, expected by the end of March 2026, for a complete and final assessment of the Group’s financial position.

Board and Management Statement

The announcement is signed by Mr. Chu Wai Hang Raymond, Chairman, Executive Director, and Chief Executive Officer, representing the Board. The Board currently comprises three executive directors and three independent non-executive directors.


Disclaimer: This article is based on a preliminary profit warning issued by Wise Ally International Holdings Limited. The information is derived from unaudited accounts and may be subject to change upon final audit. Investors are strongly advised to review the official results announcement when published and to consult with professional advisors before making any investment decisions. The author and publisher accept no liability for investment losses arising from reliance on this report.




View WISE ALLY INTL Historical chart here



China Pipe Group Limited Issues Profit Warning for 2025 with Significant Profit Decrease Expected 1

China Pipe Group Issues Profit Warning for FY2025 China Pipe Group Issues Significant Profit Warning for FY2025 Key Highlights from the Announcement Significant Decline in Profit Expected: China Pipe Group Limited has issued a...

SinoMab BioScience Receives NMPA IND Approval for SM17 in Inflammatory Bowel Disease, Expanding Therapeutic Scope Beyond Atopic Dermatitis 12

SinoMab BioScience Limited – IND Approval for SM17 in IBD SinoMab BioScience Limited Receives IND Approval from NMPA for First-in-Class SM17 in Inflammatory Bowel Disease Key Highlights IND Approval: SinoMab BioScience Limited has received...

Ever Sunshine Services Group Cancels 5.96 Million Repurchased Shares to Enhance Shareholder Value (2026) 1

Ever Sunshine Services Group Announces Cancellation of Repurchased Shares Ever Sunshine Services Group Limited: Cancellation of Repurchased Shares Key Points for Investors Share Repurchase Details: Ever Sunshine Services Group Limited recently completed a series...

   Ad